FREE Account Opening + No Clearing Fees

Par Drugs NSE SME IPO review (May apply)

Review By Dilip Davda on April 29, 2019

• PDCL is developer and manufacturer of select APIs and fine chemicals.
• Revenue includes around 90% domestic and 10% export sales.
• Few renowned buyers like Pfizer, UPL, Essential Drugs etc.
• The issue appears reasonably priced on the basis of financial parameters.

Par Drugs & Chemicals Ltd. (PDCL) is engaged in the development and manufacture of Active Pharma Ingredients ('APIs') for the domestic market as well as for exports to international markets. APIs, also known as 'bulk drugs' or 'bulk actives' are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients. The company produces various ranges of Antacid Molecules which are available in the market and are in great demand. It currently owns and operates two manufacturing facilities at Bhavnagar and Ankleshwar in Gujarat. Its Bhavnagar facility has three manufacturing blocks for different products that include APS and Fine Chemicals.

PDCL's product portfolio presently comprises 12 APIs and 6 Fine Chemical which are marketed domestically and exported. It supplies products to approximately 16 countries, including both direct and indirect exports. Key customers include Essential Drugs Company Limited, Taurus chemicals (P) Limited, Pfizer Limited, United Phosphorus Limited (Samba Jammu Unit), Shiv Silica Private Limited. Etc.

To part finance its working capital (Rs. 7.00 cr.) and general corpus fund needs (Rs. 0.89 cr.) PDCL is coming out with a maiden IPO of 1672000 equity shares of Rs. 10 each at a fixed price of Rs. 51.00 per share to mobilize Rs.8.53 Cr. It has reserved 30000 shares for eligible employees. Out of balance 1642000 shares 84000 is for the market maker, 778000 for non-retail and 780000 for retail category. The issue opens for subscription on 03.05.19 and will close on 08.05.19. Minimum application is to be made for 2000 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on NSE SME Emerge. Issue constitutes 27.18% of the post issue paid up capital of the company. PDCL is spending Rs. 0.64 cr. to mobilize Rs. 8.53 cr.

The issue is solely lead managed by Pantomath Capital Advisors Pvt. Ltd. while Link Intime India Pvt. Ltd. is the registrar to the issue. Pantomath Stock Brokers Pvt. Ltd. is acting as a market maker for the issue.

Having issued initial equity at par, PDCL converted preference shares and loans into equity at a fixed price of Rs. 66 per share in March 2019. The average cost of acquisition of shares by the promoters is Rs. 19.12 and Rs. 19.93 per share. Post issue PDCL's current paid up equity capital of Rs. 4.48 cr. will stand enhanced to Rs. 6.15 cr.

Par Drug

Par Drug
On the financial performance front, for the last three fiscals, PDCL has posted turnover/net profits of Rs. 48.81 cr. / Rs. 1.85 cr. (FY17), Rs. 42.42 cr. / Rs. 1.50 cr. (FY18) and Rs. 46.41 cr. / Rs. 2.42 cr. (FY19). Following one time mega order from one client for FY17, it posted higher the top line with the commensurate jump in the bottom-line. As on 31.03.19, its debt-equity ratio was 0.40 and the inventory turnover ratio was 11.08.

For the last three fiscals, the company has posted an average EPS of Rs. 5.69 and an average RoNW of 9.78%. The issue is priced at a P/BV of 0.78 based on its NV of Rs. 64.99 as on 31.03.19 and at a P/BV of 0.83 on the basis of post issue NAV of Rs. 61.19. If we attribute FY19 earnings on fully diluted equity post issue, then asking price is at a P/E of around 13 against industry composite average of 15.38 (as on 31.03.19). FY19 revenue consists of 89.5% of domestic sales and 10.5% of international sales.

As per offer documents, PDCL has considered Aarti Drugs, Shilpa Medicare, Vasundhara Rasayans as its listed peers that are currently trading at a P/Es of around 17.42, 25.11 and 60.52 (as on 26.04.19). However, they are strictly not comparable on an apple to apple basis.

On merchant banker's front, this is the 56th mandate from its stable in the last three fiscals. Out of the last 10 listings, all issues opened at premiums ranging from 0.05% to 11.11% on the day of listings.

Conclusion / Investment Strategy

Investors may consider investment for the long term. Based on financial parameters (including P/BV data) issue appears reasonably priced. Promoters have converted shares at Rs. 66 while the issue is priced lower. Employees too are offered shares at the same price of IPO.

Review By Dilip Davda on April 29, 2019

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

Par Drugs IPO FAQs

  1. 1. Why Par Drugs IPO?

    The initial public offer (IPO) of Par Drugs and Chemicals Limited offers an early investment opportunity in Par Drugs and Chemicals Limited. A stock market investor can buy Par Drugs IPO shares by applying in IPO before Par Drugs and Chemicals Limited shares get listed at the stock exchanges. An investor could invest in Par Drugs IPO for short term listing gain or a long term.

  2. 2. How is Par Drugs IPO?

    Read the Par Drugs IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. Par Drugs IPO what should investors do?

    Par Drugs IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Par Drugs IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Par Drugs IPO good?

    Our recommendation for Par Drugs IPO is to subscribe for long term.

  5. 5. Is Par Drugs IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe for long term to the Par Drugs IPO.

  6. 6. When will Par Drugs IPO allotment status?

    The Par Drugs IPO allotment status will be available on or around May 13, 2019. The allotted shares will be credited in demat account by May 15, 2019. Visit Par Drugs IPO allotment status to check.

  7. 7. When will Par Drugs IPO list?

    The Par Drugs IPO will list on Thursday, May 16, 2019, at NSE SME.